John Hyttel

8.5k total citations · 2 hit papers
113 papers, 7.3k citations indexed

About

John Hyttel is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Organic Chemistry. According to data from OpenAlex, John Hyttel has authored 113 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Cellular and Molecular Neuroscience, 75 papers in Molecular Biology and 20 papers in Organic Chemistry. Recurrent topics in John Hyttel's work include Neurotransmitter Receptor Influence on Behavior (61 papers), Receptor Mechanisms and Signaling (56 papers) and Neuroscience and Neuropharmacology Research (39 papers). John Hyttel is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (61 papers), Receptor Mechanisms and Signaling (56 papers) and Neuroscience and Neuropharmacology Research (39 papers). John Hyttel collaborates with scholars based in Denmark, Germany and Sweden. John Hyttel's co-authors include Jørn Arnt, J. Arnt, Connie Sánchez, A. V. Christensen, Jens Perregaard, J.‐J. Larsen, Ole Lander Svendsen, Jens‐Jørgen Larsen, Klaus P. Bøgesø and Eddi Meier and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Neurochemistry and Biochemical Pharmacology.

In The Last Decade

John Hyttel

112 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SCH 23390—The first selective dopamine D-1 antagonist

1983 662 citations John Hyttel European Journal of Pharmacology profile →
Citalopram — Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity

1982 525 citations John Hyttel profile →

Peers

Countries citing papers authored by John Hyttel

Since Specialization

Citations

This map shows the geographic impact of John Hyttel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Hyttel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Hyttel more than expected).

Fields of papers citing papers by John Hyttel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Hyttel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Hyttel. The network helps show where John Hyttel may publish in the future.

Co-authorship network of co-authors of John Hyttel

This figure shows the co-authorship network connecting the top 25 collaborators of John Hyttel. A scholar is included among the top collaborators of John Hyttel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Hyttel. John Hyttel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Differentiation of classical and novel antipsychotics using animal models 1997 ·International Clinical Psychopharmacology ·Jørn Arnt, Torben Skarsfeldt, John Hyttel	24
2	Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity 1995 ·Journal of Medicinal Chemistry ·Klaus P. Bøgesø, Jørn Arnt, Kristen Frederiksen, H O Hansen, John Hyttel, Henrik Pedersen	38
3	Pharmacological characterization of Lu 25-109-T, a compound with M 1 -agonistic and M 2 /M 3 -antagonistic effects on muscarinic receptors. 1995 ·Life Sciences ·Eddi Meier, J. Arnt, Kristen Frederiksen, (unknown), (unknown), Torben Skarsfeldt, Nils Dragsted, Henrik Pedersen, John Hyttel	2
4	Selective, centrally acting serotonin 5-HT2 antagonists. 1. 2- and 6-Substituted 1-phenyl-3-(4-piperidinyl)-1H-indoles 1992 ·Journal of Medicinal Chemistry ·Jens Perregaard, Kim Andersen, John Hyttel, Connie Sánchez	13
5	The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer 1992 ·Journal of Neural Transmission ·John Hyttel, (unknown), Jens Perregaard, (unknown)	271
6	Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro 1992 ·European Journal of Pharmacology ·Jørn Arnt, John Hyttel, Connie Sánchez	124
7	Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles 1992 ·Journal of Medicinal Chemistry ·Jens Perregaard, (unknown), Klaus P. Boegesoe, John Hyttel, Connie Sánchez	67
8	Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists 1991 ·Journal of Medicinal Chemistry ·Klaus P. Boegesoe, Tommy Liljefors, (unknown), John Hyttel, Henrik Pedersen	20
9	Effect of a dopamine D-1 agonist in rats treated chronically with zuclopenthixol 1990 ·Life Sciences ·Birte Glenthøj, Jørn Arnt, John Hyttel	6
10	Dopamine D-2 agonists with high and low efficacies: differentiation by behavioural techniques 1990 ·Journal of Neural Transmission ·J. Arnt, John Hyttel	30
11	Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI 1989 ·European Journal of Pharmacology ·Jørn Arnt, John Hyttel	119
12	Selective Dopamine D1 and D2 Receptor Antagonists 1989 ·PubMed ·John Hyttel, J. Arnt, (unknown)	15
13	Parallel Decrease in the Density of Dopamine D₁ and D₂ Receptors in Corpus Striatum of Rats from 3 to 25 Months of Age 1989 ·Pharmacology & Toxicology ·John Hyttel	17
14	Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity 1988 ·Journal of Medicinal Chemistry ·Klaus P. Bøgesø, (unknown), (unknown), A. V. Christensen, John Hyttel, Karsten Gjessing Jensen	33
15	EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors 1988 ·European Journal of Pharmacology ·Gabriel Nowak, Jørn Arnt, John Hyttel	26
16	Relative Dopamine D₁and D₂Receptor Affinity and Efficacy Determine Whether Dopamine Agonists Induce Hyperactivity or Oral Stereotypy in Rats 1988 ·Pharmacology & Toxicology ·Jørn Arnt, Klaus P. Bøgesø, John Hyttel, Eddi Meier	108
17	Inactivation of dopamine D-1 or D-2 receptors differentially inhibits stereotypies induced by dopamine agonists in rats 1988 ·European Journal of Pharmacology ·Jørn Arnt, John Hyttel, Eddi Meier	62
18	Age Related Decrease in the Density of Dopamine D₁ and D₂ Receptors in Corpus Striatum of Rats 1987 ·Pharmacology & Toxicology ·John Hyttel	61
19	Ontogeny of dopamine D1 receptors in rat striatum 1986 ·Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) ·Wanyun Zeng, John Hyttel, L. Charles Murrin	2
20	A comparison of the effect of neuroleptic drugs on the binding of 3H-haloperidol and 3H-cis(Z)-flupenthixol and on adenylate cyclase activity in rat striatal tissue in vitro 1978 ·Progress in Neuro-Psychopharmacology ·John Hyttel	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact